See today's BioWorld
To read the full story, subscribe or sign in.

CP-101 hits primary endpoint in phase II CDI trial, but will Finch take flight?

June 23, 2020
By Cormac Sheridan
DUBLIN – Top-line data from a phase II pivotal trial of CP-101, Finch Therapeutics Group Inc.’s oral microbiome therapy for chronic Clostridioides difficile infection (CDI), are technically good, but how good is the big question.
BioWorld Clinical Infection Microbiome